Hosted on MSN1mon
RATP Dev finalises study for AlUla’s 360 Mobility PlanRATP Group subsidiary RATP Dev has concluded a comprehensive study to implement the 360 Mobility Plan for the Royal Commission for AlUla (RCU), marking a step in the development of “sustainable ...
Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for RAPT Therapeutics in a note issued to investors ...
Explore RAPT Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RAPT. RAPT Therapeutics partners with Shanghai Jemincare to develop RPT904 ...
“Our focus for 2025 will be on advancing development of RPT904, a novel, potentia Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected ...
March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics ... “Our focus for 2025 will be on advancing development of RPT904, a novel, potential best-in-class option to treat the large and ...
Our focus for 2025 will be on advancing development of RPT904, a novel, potential best-in-class option to treat the large and underserved ...
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies ...
General and administrative expenses for the fourth quarter of 2024 were $8.0 million, compared to $6.5 million for the same period in 2023. The increase in general and administrative expenses was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results